Diadema Partners LP Nektar Therapeutics Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Nektar Therapeutics stock. As of the latest transaction made, Diadema Partners LP holds 698,919 shares of NKTR stock, worth $649,994. This represents 0.28% of its overall portfolio holdings.
Number of Shares
698,919Holding current value
$649,994% of portfolio
0.28%Shares
1 transactions
Others Institutions Holding NKTR
# of Institutions
152Shares Held
131MCall Options Held
92.7KPut Options Held
4.9K-
Black Rock Inc. New York, NY15.2MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$11.5 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.67MShares$8.99 Million0.14% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.81MShares$7.26 Million0.37% of portfolio
-
Acadian Asset Management LLC Boston, MA7.2MShares$6.7 Million0.02% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $174M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...